FY2026 EPS Estimate for Bausch Health Cos Raised by Analyst

Key Points

• Zacks Research raised Bausch Health’s FY2026 EPS estimate to $4.24 from $3.93, matching the current consensus forecast, while maintaining a “Strong Sell” rating.
• Bausch Health’s latest quarterly results beat expectations, with EPS of $1.26 versus the $0.96 consensus and revenue of $2.83 billion versus $2.59 billion expected.
• The stock opened at $6.88, while analysts’ consensus rating remains “Reduce” with an average price target of $8.00; institutional investors own 78.65% of shares.

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Equities research analysts at Zacks Research boosted their FY2026 EPS estimates for Bausch Health Cos in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now expects that the company will post earnings per share of $4.24 for the year, up from their prior estimate of $3.93. Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.24 per share. Zacks Research also issued estimates for Bausch Health Cos' Q4 2026 earnings at $1.16 EPS.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. The company had revenue of $2.83 billion during the quarter, compared to the consensus estimate of $2.59 billion.

A number of other analysts have also commented on BHC. Jefferies Financial Group raised Bausch Health Cos to a "hold" rating in a report on Wednesday, July 22nd. Weiss Ratings upgraded Bausch Health Cos from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, July 31st. Royal Bank Of Canada cut their target price on Bausch Health Cos from $10.00 to $9.00 and set a "sector perform" rating on the stock in a research report on Monday, April 27th. Finally, Wall Street Zen upgraded Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 1st. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average target price of $8.00.

Bausch Health Cos Price Performance

Shares of NYSE BHC opened at $6.88 on Thursday. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -2.32 and a beta of 0.38. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.44. Bausch Health Cos has a fifty-two week low of $4.33 and a fifty-two week high of $8.00. The firm's 50-day simple moving average is $5.30 and its 200 day simple moving average is $5.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the 1st quarter worth approximately $68,000. Jones Financial Companies Lllp lifted its stake in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock valued at $162,000 after purchasing an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Bausch Health Cos by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock valued at $6,136,000 after purchasing an additional 467,270 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Bausch Health Cos by 3.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock valued at $2,102,000 after purchasing an additional 9,834 shares during the period. Finally, Geode Capital Management LLC increased its position in Bausch Health Cos by 11.2% in the second quarter. Geode Capital Management LLC now owns 840,418 shares of the company's stock worth $5,597,000 after buying an additional 84,892 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source